ATE433452T1 - Imidazoä1,2-cüpyrimidinylessigsäurederivate - Google Patents

Imidazoä1,2-cüpyrimidinylessigsäurederivate

Info

Publication number
ATE433452T1
ATE433452T1 AT05706922T AT05706922T ATE433452T1 AT E433452 T1 ATE433452 T1 AT E433452T1 AT 05706922 T AT05706922 T AT 05706922T AT 05706922 T AT05706922 T AT 05706922T AT E433452 T1 ATE433452 T1 AT E433452T1
Authority
AT
Austria
Prior art keywords
diseases
allergic
imidazo
acid derivative
treatment
Prior art date
Application number
AT05706922T
Other languages
English (en)
Inventor
Tai-Wei Ly
Takashi Yoshino
Yuki Takekawa
Takuya Shintani
Hiromi Sugimoto
Kevin B Bacon
Klaus Urbahns
Original Assignee
Actimis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimis Pharmaceuticals Inc filed Critical Actimis Pharmaceuticals Inc
Application granted granted Critical
Publication of ATE433452T1 publication Critical patent/ATE433452T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/04Antipruritics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/06Antipsoriatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AT05706922T 2004-01-31 2005-01-19 Imidazoä1,2-cüpyrimidinylessigsäurederivate ATE433452T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP04002144 2004-01-31
PCT/EP2005/000475 WO2005073234A2 (en) 2004-01-31 2005-01-19 Imidazo[1,2-c]pyrimidinylacetic acid derivatives

Publications (1)

Publication Number Publication Date
ATE433452T1 true ATE433452T1 (de) 2009-06-15

Family

ID=34814234

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05706922T ATE433452T1 (de) 2004-01-31 2005-01-19 Imidazoä1,2-cüpyrimidinylessigsäurederivate

Country Status (23)

Country Link
US (1) US7750014B2 (de)
EP (1) EP1718649B1 (de)
JP (1) JP4996257B2 (de)
KR (1) KR101207428B1 (de)
CN (1) CN100584844C (de)
AT (1) ATE433452T1 (de)
AU (1) AU2005209381B2 (de)
BR (1) BRPI0507123A (de)
CA (1) CA2551778C (de)
CY (1) CY1109274T1 (de)
DE (1) DE602005014849D1 (de)
DK (1) DK1718649T3 (de)
ES (1) ES2326896T3 (de)
IL (1) IL177083A (de)
MX (1) MXPA06007674A (de)
NO (1) NO20063878L (de)
NZ (1) NZ548396A (de)
PL (1) PL1718649T3 (de)
PT (1) PT1718649E (de)
RU (1) RU2373208C2 (de)
SI (1) SI1718649T1 (de)
WO (1) WO2005073234A2 (de)
ZA (1) ZA200605387B (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2404163C2 (ru) 2004-12-27 2010-11-20 Актелион Фармасьютиклз Лтд Производные 2,3,4,9-тетрагидро-1h-карбазола в качестве антагонистов рецептора crth2
CA2658986C (en) 2006-08-07 2014-11-25 Actelion Pharmaceuticals Ltd (3-amino-1,2,3,4-tetrahydro-9h-carbazol-9-yl)-acetic acid derivatives
KR20100015499A (ko) * 2007-04-13 2010-02-12 노파르티스 아게 Gpbar1 효능제로서의 피리다진-, 피리딘- 및 피란-유도체
US8507005B2 (en) * 2007-06-21 2013-08-13 Actimis Pharmaceuticals, Inc. Particulates of a CRTH2 antagonist
BRPI0817318A2 (pt) * 2007-09-25 2015-03-17 Actimis Pharmaceuticals Inc Composto, composição farmacêutica, e, método para tratar uma doença, ou uma condição, ou sintoma da mesma.
AU2008305632B2 (en) 2007-09-25 2014-01-30 Actimis Pharmaceuticals, Inc. Alkylthio pyrimidines as CRTH2 antagonists
US8242145B2 (en) 2008-02-14 2012-08-14 Panmira Pharmaceuticals, Llc Cyclic diaryl ether compounds as antagonists of prostaglandin D2 receptors
EP2268611A2 (de) 2008-04-02 2011-01-05 Amira Pharmaceuticals, Inc. Aminoalkylphenyl-antagonisten von prostaglandin-d2-rezeptoren
US8541419B2 (en) 2008-09-02 2013-09-24 Actimis Pharmaceuticals, Inc. Isotopically enriched pyrimidin-5-yl acetic acid derivatives as CRTH2 antagonists
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
CN102791689B (zh) 2010-03-22 2014-10-29 埃科特莱茵药品有限公司 3-(杂芳基-氨基)-1,2,3,4-四氢-9h-咔唑衍生物及其作为前列腺素d2受体调节剂的用途
TW201201805A (en) 2010-07-05 2012-01-16 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin D2 receptor modulators
DE102011003315A1 (de) 2011-01-28 2012-08-02 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimindine und Triazine und ihre Verwendung
DE102010031149A1 (de) 2010-07-09 2012-01-12 Bayer Schering Pharma Aktiengesellschaft Annellierte Pyrimidine und Triazine und ihre Verwendung
PE20130779A1 (es) 2010-07-09 2013-06-21 Bayer Ip Gmbh Pirimidinas y triazinas condensadas y su uso
US8927559B2 (en) 2010-10-11 2015-01-06 Merck Sharp & Dohme Corp. Quinazolinone-type compounds as CRTH2 antagonists
EP2457900A1 (de) 2010-11-25 2012-05-30 Almirall, S.A. Neue Pyrazolderivate mit CRTH2-antagonistischem Verhalten
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
AU2012351342A1 (en) 2011-12-16 2014-07-24 Atopix Therapeutics Limited Combination of CRTH2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
EP2794563B1 (de) 2011-12-21 2017-02-22 Actelion Pharmaceuticals Ltd Heterocyclyl-derivate und ihre verwendung als prostaglandin-d2-rezeptormodulatoren
DE102012200360A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte Triazine und ihre Verwendung
DE102012200349A1 (de) 2012-01-11 2013-07-11 Bayer Intellectual Property Gmbh Substituierte annellierte Pyrimidine und Triazine und ihre Verwendung
US9498480B2 (en) 2012-03-06 2016-11-22 Bayer Intellectual Property Gmbh Substituted azabicycles and use thereof
WO2014006585A1 (en) 2012-07-05 2014-01-09 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
MX384987B (es) 2014-03-17 2025-03-14 Idorsia Pharmaceuticals Ltd Derivados del ácido acético azaindol y su uso como moduladores de receptor de prostaglandina d2.
EP3119780B1 (de) 2014-03-18 2018-08-29 Idorsia Pharmaceuticals Ltd Azaindolessigsäurederivate und deren verwendung als prostaglandin-d2-rezeptormodulatoren
JP6833852B2 (ja) 2015-09-15 2021-02-24 イドーシア ファーマシューティカルズ リミテッドIdorsia Pharmaceuticals Ltd 結晶形
KR20190103507A (ko) 2018-02-12 2019-09-05 김강민 지하철 혼잡도 알림 시스템
WO2019139462A2 (ko) * 2019-02-21 2019-07-18 엘지전자 주식회사 하차 시점 알림 방법 및 사용자 단말
TW202100015A (zh) 2019-02-28 2021-01-01 瑞士商先正達農作物保護公司 具有含硫取代基之殺有害生物活性雜環衍生物
CN114681438B (zh) * 2022-05-17 2024-03-19 中国医学科学院基础医学研究所 二甲双胍及其它含胍化合物在逆转Gal-10结晶趋势并缓解相关疾病中应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
GB9125842D0 (en) 1991-12-04 1992-02-05 Ici Plc Heterocyclic derivatives
ID29514A (id) * 1999-11-10 2001-09-06 Ortho Mcneil Pharmacetical Inc 2-ARIL-3-(HETEROARIL)-IMIDAZO [1,2-a]PIRIMIDIN TERSUBSTITUSI, DAN METODE-METODE DAN KOMPOSISI-KOMPOSISI FARMASI YANG TERKAIT
JP2001302667A (ja) * 2000-04-28 2001-10-31 Bayer Ag イミダゾピリミジン誘導体およびトリアゾロピリミジン誘導体
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
EP1413306A1 (de) 2002-10-21 2004-04-28 Warner-Lambert Company LLC Tetrahydrochinolin-Derivate als CRTH2 Antagonisten
EA011087B1 (ru) * 2002-12-20 2008-12-30 Эмджен Инк. Соединения и фармацевтические композиции для лечения воспалительных заболеваний
ATE316077T1 (de) 2003-04-25 2006-02-15 Actimis Pharmaceuticals Inc Pyrimidin-essigsäure derivate geeignet zur behandlung von crth2-bedingten krankheiten

Also Published As

Publication number Publication date
CN100584844C (zh) 2010-01-27
IL177083A0 (en) 2006-12-10
NZ548396A (en) 2010-06-25
ZA200605387B (en) 2008-05-28
JP4996257B2 (ja) 2012-08-08
BRPI0507123A (pt) 2007-06-19
CA2551778C (en) 2013-10-22
PL1718649T3 (pl) 2009-11-30
KR20060130187A (ko) 2006-12-18
DK1718649T3 (da) 2009-08-24
HK1101969A1 (en) 2007-11-02
US7750014B2 (en) 2010-07-06
AU2005209381A1 (en) 2005-08-11
CN1938310A (zh) 2007-03-28
DE602005014849D1 (de) 2009-07-23
WO2005073234A3 (en) 2005-10-06
RU2373208C2 (ru) 2009-11-20
US20090012102A1 (en) 2009-01-08
IL177083A (en) 2011-10-31
EP1718649B1 (de) 2009-06-10
SI1718649T1 (sl) 2009-10-31
CY1109274T1 (el) 2014-07-02
WO2005073234A2 (en) 2005-08-11
AU2005209381B2 (en) 2011-06-30
JP2007519659A (ja) 2007-07-19
EP1718649A2 (de) 2006-11-08
MXPA06007674A (es) 2006-09-04
PT1718649E (pt) 2009-08-06
RU2006131304A (ru) 2008-03-10
KR101207428B1 (ko) 2012-12-04
ES2326896T3 (es) 2009-10-21
NO20063878L (no) 2006-10-11
CA2551778A1 (en) 2005-08-11

Similar Documents

Publication Publication Date Title
CY1109274T1 (el) Παραγωγα ιμιδαζο[1,2-c] πυριμιδινυλοξικου οξεος
TW200505873A (en) Pyrimidine derivatives
EP2380891B1 (de) Substituierte Piperidino-Dihydrothienopyrimidine
MXPA05010055A (es) Derivados de 2-fenoxi- y 2-fenil-sulfomamida con actividad antagonista del ccr3, para el tratamiento del asma y otros desordenes inflamatorios o inmunologicos.
JO3041B1 (ar) مركبات جديدة مفيدة لمعالجة الأمراض التنكسية والالتهابية
US20090137608A1 (en) Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine H4 receptor
BR0314830A (pt) Derivados de azol-pirimidina fundida
NO996490L (no) Substituerte benzanilider som CCR5-reseptorligander, anti- inflammatoriske midler og antivirale midler
WO2004011427A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
EA201100079A1 (ru) Производные триазоло[4,5-d]пирамидина и их применение в качестве антагонистов пуринового рецептора
CY1117974T1 (el) ΥΠΟΚΑΤΕΣΤΗΜΕΝΑ ΠΑΡΑΓΩΓΑ 1,2,3,4-ΤΕΤΡΑΫΔΡΟΚΥΚΛΟΠΕΝΤΑ[b]ΙΝΔΟΛ-3-ΥΛ-ΟΞΙΚΟΥ ΟΞΕΟΣ ΧΡΗΣΙΜΑ ΣΤΗΝ ΑΓΩΓΗ ΑΥΤΟΑΝΟΣΩΝ ΚΑΙ ΦΛΕΓΜΟΝΩΔΩΝ ΔΙΑΤΑΡΑΧΩΝ
MY157036A (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
WO2004010943A3 (en) Substituted benzanilides as modulators of the ccr5 receptor
EA200802417A1 (ru) Замещенные фенилуксусные кислоты как dp-2-антагонисты
HRP20110414T1 (hr) Indoli i njihova uporaba u liječenju
NZ595307A (en) Atropisomers of 2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
NO20091489L (no) Tiazolpyrazolopyridiner som CRF1 reseptorantagonister
NO20083358L (no) Piperasinyl derivater som modulatorer for kjemokine reseptor aktivitet
BRPI0409393A8 (pt) composto, composição farmacêutica, e, métodos para modulação de atividade de receptor de quimiocina em um mamífero, para tratamento, melhora, controle ou redução do risco de um distúrbio ou doença inflamatório e imunorregulatório, e de artrite reumatóide
JP2015517587A5 (de)
WO2004010942A3 (en) Substituted heterocyclic compounds as modulators of the ccr5 receptor
NO20082297L (no) Piperazinderivater som er anvendelige som CCR5-antagonister
DE60011997D1 (de) SUBSTITUIERTE BENZO(1,2-b:5,4-b')DIPYRAN-4-AMINE ALS CCR5 MODULATOREN
Xia et al. Substituted dipiperidine alcohols as potent CCR2 antagonists
WO2005058898A3 (en) Purine compounds which can be used as phosphodiesterase (pde) type iv inhibitors

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1718649

Country of ref document: EP